GO
| HSI1 | 27,023.67 | -242.71 | 127.26B |
| HSCEI1 | 9,178.84 | -89.34 | 46.35B |
| Back Zoom + Zoom - Block Traded | |
|
2026-02-12 10:04:54 Morgan Stanley released a research report predicting that the share price of WUXI BIO (02269.HK) will rise in the next 45 days, with a probability for the scenario estimated between 70% and 80%. The Company recently issued a positive profit alert, with management guidance at an event that growth will accelerate in FY2026, a 16% increase in the number of integrated projects in 2025 and the strong momentum in research services, reflecting that the Company's 2026 performance will be robust. Meanwhile, the momentum in research services will bring IP-related revenue, further enhancing profitability. Recently, the Company also reached out-licensing deals with Vertex and ZAI LAB (09688.HK). Due to the accelerated revenue growth and margin expansion of WUXI BIO, the broker raised its 2026-2030 earnings forecasts by 4-10%, and lifted its target price from $45 to $50, with rating kept at Overweight, according to another research report from Morgan Stanley. This morning (12th), WUXI BIO opened 2.71% higher, and peaked at $44, setting an over-2-year high since November 2023. It last printed at $43.46, advancing 4.98%, with a trading volume of 24.8934 million shares, involving $1.082 billion. ~ AASTOCKS Financial News Website: www.aastocks.com | |